Drug Development

With validated Phase 1b data, ONL Therapeutics' novel drug aims to protect vision cells, not just slow disease, in a challenge to current GA therapies.

The biotech is advancing a promising myelofibrosis therapy while developing a next-gen 'super drug,' a dual strategy signaling significant growth.

A new partnership aims to advance a novel antibody for FTLD, a devastating dementia, showcasing a powerful model for biotech innovation and strategic growth.

Boston-based 1910 Genetics unveils an AI model that bypasses decades-old barriers, opening a vast new frontier for treating Alzheimer's and Parkinson's.

The PAS 2026 meeting is more than a conference; it's a convergence of science, capital, and community, signaling major shifts in pediatric care.

A regulatory filing shows hedge fund Balyasny's active trading in Avadel Pharma, exposing a merger arbitrage strategy amid a fierce bidding war.